



FLEISHMANHILLARD


ENDOCRINE DISRUPTORS IN THE EU

*Highlights from the ED fitness
check public consultation ...*

EDs continue to be an issue of concern for many groups...


Who responded to the survey?

- ☐ *Academic/research institution*
- ☒ *Business association*
- ☐ *Civil society organisation*
- ☒ *Company/business organisation*
- ☐ *Other*
- ☒ *Public authority*
- ☐ *Trade union*



Without harmonised criteria it is more difficult to identify EDs...

The lack of harmonized ED criteria is ...




□ *An important problem*

■ *Not a problem*


Participants disagree on whether current regulation is effective...

Does this regulation protect consumers by minimising exposure to EDs?



Regulatory requirements increase total operating costs...

Has the implementation of regulatory requirements for endocrine disruptors increased your total operating costs?




Three takeaways

1. *These results show that EDs remain a divisive issue among stakeholders;*
2. *As most believe that the current data requirements and testing are insufficient, the scene is set for the Commission to take action;*
3. *The outcomes resonate with the concerns raised in the European Parliament and by Member States.*

What's next?

- *The Member States and Commission are exploring the option of including EDs in the CLP Regulation and GHS;*
- *The full Fitness Check report will likely be presented in parallel with the Chemicals strategy for sustainability in Q3/Q4 of 2020;*
- *Looking further ahead, EDs will likely also be addressed through the Zero-Pollution Europe agenda.*



**Get in touch if
you would like to
discuss this in
depth.**

Peter Holdorf

FleishmanHillard Brussels

peter.holdorf@fleishmaneuropa.com